Prokarium

Prokarium company information, Employees & Contact Information

Updated May 2026

Quick answer

Prokarium is a Biotechnology Research company. It has approximately 19 employees on record. Contact data was last refreshed in May 2026. Find Prokarium's verified employee emails, phone numbers, headquarters address, and key decision makers below.

Explore related pages

Related company profiles:

Prokarium is pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects.

Company Details

Employees
19
Address
2 Royal College Street, London,england,united Kingdom
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
London, England
Looking for a particular Prokarium employee's phone or email?

Prokarium Questions

News

Prokarium Expands IP Portfolio With Two New U.S. Patents Strengthening Its Position in Bladder Cancer - Business Wire

Prokarium Expands IP Portfolio With Two New U.S. Patents Strengthening Its Position in Bladder Cancer Business Wire

Prokarium begins clinical trial of bladder cancer immunotherapy - Clinical Trials Arena

Prokarium begins clinical trial of bladder cancer immunotherapy Clinical Trials Arena

Prokarium bolsters IP portfolio with two new US patents - Pharmaceutical Technology

Prokarium bolsters IP portfolio with two new US patents Pharmaceutical Technology

Study launches exploring immunotherapy regimen in NMIBC - Urology Times

Study launches exploring immunotherapy regimen in NMIBC Urology Times

This Oral Vaccine for Typhoid Raises €8M from International Investors - Labiotech.eu

This Oral Vaccine for Typhoid Raises €8M from International Investors Labiotech.eu

Prokarium Achieves Milestone with First Patient Dosing in PARADIGM-1 Non-Muscle Invasive Bladder Cancer Clinical Trial - Via TT

Prokarium Achieves Milestone with First Patient Dosing in PARADIGM-1 Non-Muscle Invasive Bladder Cancer Clinical Trial Via TT

Prokarium Appoints Kristen Albright as Chief Executive Officer - Business Wire

Prokarium Appoints Kristen Albright as Chief Executive Officer Business Wire

Prokarium Acquires Emergent’s Oral Vaccine Technology - Contract Pharma

Prokarium Acquires Emergent’s Oral Vaccine Technology Contract Pharma

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant